Type 2 diabetes is the original GLP-1 receptor agonist indication. Every major GLP-1 RA (semaglutide, tirzepatide, dulaglutide, liraglutide) is FDA-approved for T2D. The drug class produces clinically meaningful A1c reduction (1.5–2.5%), weight loss, and — in some agents — CV risk reduction (LEADER, SUSTAIN-6, REWIND).
The evidence
Ozempic for T2D was approved 2017 based on SUSTAIN program. Mounjaro for T2D approved 2022 based on SURPASS program (SURPASS-3 showed tirzepatide superior to titrated insulin degludec on A1c and weight). LEADER (liraglutide 2016), REWIND (dulaglutide 2019), SUSTAIN-6 (semaglutide 2016) established CV benefit in T2D.
FDA-approved labeling status
FDA-approved labeled use. Most commercial insurance covers Ozempic, Mounjaro, Trulicity for T2D. Typical copay $25–$100/mo with PA.
Practical considerations
GLP-1 RAs are now first- or second-line agents in T2D guidelines (ADA, AACE) for most patients, especially those with obesity or established CVD. Combined GLP-1 + SGLT2 inhibitor is increasingly common.
See also
SUSTAIN trial program · SURPASS trial program · Insurance coverage by carrier